
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in Australia
Marks BRUKINSA’s second approved indication in Australia, on the heels of its recent initial approval in Waldenström’s macroglobulinemia To date, BRUKINSA is approved in mantle […]


